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ABSTRACT 
snR31 Is a RNA species of 225 nt. which has the tri-
methyl guanosine cap structure typical of small nuclear 
RNAs (snRNAs) and yeast small nucleolar RNAs 
(snoRNAs), and Is associated with the nucleolar 
proteins flbrillarln (NOP1) and GAR1. On sub-nuclear 
fractlonatlon, snR31 behaves like other snoRNAs, and 
Is enriched in a nucleolar fraction. The SNR31 genomic 
locus is close to the SNR5 locus, which encodes 
another snoRNA. The two genes are divergently 
transcribed with 217 bp separating the transcription 
start sites. Disruption of the SNR31 gene does not 
detectably impair growth in a haploid strain. Analyses 
of pre-rRNA processing In wild-type and snr31-
strains shows some accumulation of the 35S primary 
transcript In the mutant, indicating a mild Impairment 
of the initial steps in pre-rRNA processing. 
INTRODUCTION 
The transcription ofpre-ribosomal RNA (pre-rRNA), and most 
post-transcriptional steps in ribosome synthesis, take place in the 
nucleolus, a specialized sub-nuclear structure. In recent years 
it has become clear that the processing of pre-ribosomal RNA, 
and perhaps other steps in ribosome synthesis, requires the action 
of a class of small RNA species localized to the nucleolus, the 
small nucleolar RNAs (snoRNAs). The cloning and 
characterization of 11 yeast snoRNAs has previously been 
reported. Of these, three species, U3, U14 and snR30, are 
essential for cell viability, while mutants lacking snR 1 0 are 
impaired in growth (1-4). The absence of any of these snoRNAs 
results in the accumulation of the 35S primary transcript of pre-
rRNA, and inhibition of the processing steps which normally lead 
to the synthesis of the small subunit rRNA (18S in yeast). 
Synthesis of the large subunit rRNA (25S in yeast) is little 
affected. Disruption of the genes encoding the other cloned 
snoRNAs (snR3, snR4, snRs, snR8, snR9, snR189 and snRl90) 
(5 - 8) does not detectably impair growth. Even a sextuple mutant 
lacking simultaneously snR3, snR4, snR5, snR8, snR9 and 
snR1O, is not more impaired in growth than an snR10 single 
mutant strain (5). The snoRNAs are associated with proteins in 
small nucleolar ribonucleoprotein particles (snoRNPs). The 
cloning of four yeast snoRNP proteins, NOPI, GAR1, SOFl 
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and SSB1, has been reported. Of these, NOPI (the yeast 
homologue of the vertebrate nucleolar protein fibrillarin) appears 
to be associated with all yeast snoRNAs, while the others are 
associated with subsets of the snoRNAs (9-12) 
A large number of snoRNA species are also likely to be present 
in higher eukaryotes. At the time of writing, the cloning of 10 
human snoRNAs (U3, U8, U13, U14, U15, U16, Ul7, El, E2, 
E3) has been reported (13 - 18), and the number is rising rapidly. 
Of these, functional analyses in vivo using Xenopus oocytes have 
been reported for U3 and U8 (19, 20). In contrast to the results 
of genetic analyses in yeast, destruction of theseRNAs by micro-
injection of complementary DNA oligonucleotides, interferes with 
synthesis of the large subunit rRNA, but not the small subunit 
rRNA. In addition, analyses in vitro indicate that U3 is also 
required for a cleavage event in the 5' external transcribed spacer 
(21, and references therein). 
Here we report the sequence, characterization and initial 
functional analysis of a novel yeast snoRNA, which is non-
essential but has a mild effect on the processing of pre-rRNA. 
MATERIALS AND METHODS 
Strains and media 
Standard S. cerevisiae growth and handling techniques were 
employed. Transformation was by the Li Cl method (22). The 
diploid strain used for gene disruption carries MA Ta/OI. , ade8/ +, 
his4/ +, his3/ +, ade2lade2, leu211eu2, lyslllys1, ura31ura3 
(strain JU42 x JR26-19B; kindly provided by Eduard Hurt). The 
haploid SNR31+ strain carries, MA Ta, ura3-52, leu2-3.112, 
ade1-100, his4-519 (strain BWGl-7A; kindly provided by 
L.Guarente). The strain used for analysis of the effects of the 
absence of snR31 is isogenic except that it has the snr 31: : URA3 
construct integrated at the SNR31 locus. 
Cloning 
For gene disruption, the XhoI - BglII genomic fragment carrying 
SNR31 was subcloned into the XhoI - BamHI sites of pBS (KS + ). 
The EcoRI - XmnI region of SNR31 was replaced by the 
EcoRI -SmaI fragment of YIp5, which includes the TEJR and 
URA3 genes. This deletes 9 nucleotides of 5' flanking sequence 
and 159 nucleotides of SNR31 coding sequence. The linear 
fragment, SNR31 5' flanking sequence-TEJR-URA3-SNR31 3' 
flanking sequence, was used to transform a diploid strain of yeast, 
with selection for psURA3+ . Following sporulation, URA3+ 
haploid progeny could be recovered, demonstrating that SNR31 
is not essential for spore germination or growth. The same 
construct was subsequently used to transform a haploid strain 
of yeast (BWG 1-7 A) to produce otherwise isogenic SNR31 and 
snr31::URA3 strains . 
RNA extraction and analysis 
RNA extraction, polyacrylamide and agarose-formaldehyde gel 
electrophoresis and hybridization were performed as described 
(4), except that Hybond-N + (Amersham) was used for all 
Northern hybridizations. The vectors previously described (23) 
were used to synthesize riboprobes for U3, U14, snRlO, snR30, 
snR190, U4, U5 and U6 hybridizations. The EcoRI-XmnI 
restriction fragment including the SNR31 coding sequence, was 
cloned into the riboprobe vector pT3/T7a-19 (BRL). This vector 
was then transcribed using T7 RNA polymerase to generate 
riboprobes for hybridization to snR31 . The hybridization probe 
to the 5' region of ITS I was an oligonucleotide of sequence, GC-
TCTTTGCTCTTGCC. The 3' region of ITS I was amplified by 
PCR using primers which insert EcoRI and HindIII sites at 
cleavage sites A2 and B. respectively. This fragment was cloned 
into pT3/T7a-IS (BRL) and used to prepare riboprobes. 
The primer extension to determine the 5' end of snR31 was 
performed in molar excess of primer as described (24) except 
that Actinomycin D was omitted from the extension buffer. 
Annealing and extension were carried out at 46°C. After 
extension with AMV reverse transcriptase, the RNA was 
hydrolyzed and the DNA was precipitated and run on a 
sequencing gel. The same oligonucleotide was used to obtain a 
sequence ladder and was first kinased with unlabeled A TP so 
as to ensure identical migration. The oligonucleotide used (GC-
ACTGAAGCAACGCCC) is complementary to nucleotides 
76-92 of snR31. 
RNase protection to determine the 5' and 3' ends of snR31 
was performed as described (25) , except that 0.2 u of RNase 
H was added per reaction. RNases A + T1 , were used with anti-
sense RNA transcribed from the genomic XmnI - EcoRI and 
PvuII - XmnI fragments (see Figure I) subcloned in to 
pT3/T7cx-19. 
Immunoprecipitation 
Lysate was prepared from strain BWGl-7A following growth 
in glucose minimal medium. Lysis and immunoprecipitation were 
as previously described (9), except that the cell lysis buffer for 
immunoprecipitation contained 150 mM KAc, 20 mM Tris Ac 
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Figure 1. Restriction map of the SNR5 - SNR31 region. The restriction map is 
shown for a 2.3 kb genomic BamHI partial fragment in plasmid pES3 , in which 
the BamHI sites have been ligated to vector EcoRV sites (E.Schuster and 
C.Guthrie, personal communication). Sites shown are A = AceI , B = BamHI, 
Bg = BglII, E = EcoRl, EV = EcoRV, N = NdeI, P = PvuI, X = XmnI, 
Xh = XhoI. No sites were detected for Bell, HindIII , HpaI, Kpnl, NcoI, NotI, 
NruI, PstI, Sac!, Sail, SphI, StuI, XbaI or XmaI in this region. SNR31 and SNR5 
are divergently transcribed as shown. 
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pH 7.5,5 mM MgAc, 5 mM VRC (BRL), 0.2% Triton X-lOO 
and 2 mM PMSF. The same buffer, without VRC and PMSF, 
was used for antibody binding and washing. Antibodies against 
NOPl and GARI were affinity purified as previously described 
(9, 10). Immunoprecipitation was for 2 hours at 4°C using lysate 
prepared from the equivalent of 5 OD600 unit of cells (about 108 
cells). Under these conditions the lysate is present in excess. 
Precipitated RNAs were recovered and analyzed as previously 
described (9). 
Sub-cellular fractionation 
Cell fractionation and subnuclear fractionation were carried out 
as described (9, 26). 
RESULTS 
The cloning of SNR5 has previously been reported (5). When 
we used the genomic clone as a hybridization probe, we observed, 
in addition to snR5 , a second, larger RNA which we designated 
snR31. Subcloning of the region showed that the second RNA 
is encoded by sequences 5' to the SNR5 gene. Riboprobes 
prepared to this region showed that snR31 is transcribed on the 
opposite strand from snR5 with a divergent transcription pattern 
- 600 TCCTTATCCT TTGACAGTAA AATTCAAAAA AC TCACTAGA AAGTTCACTA -551 
-55 0 AAGCGCCTTA GCTGACTACA GCACAACCCA ACCCCAAAAA CTAGTGAACT - 501 
- 500 ACACACTAAG AGAATTTATG GTATTTCCAT AATTGAAGTA TATGTACGAT - 45 1 
OHUC ACUUCUAUAC AUGUGGAUCU soR5 
- 450 GTATACAATG TAAACAAGAG AGTAATGAAG TGAAGATATG TACACCTAGA -40 1 
CGCUUGGUUA CUAUUAAACA AAAGAAUUAA UUCUUUUUGG UAAUUUUGAC snR5 
-4 00 GCGAACCAAT GATAATTTGT TTTCTTAATT AAGAAAAACC ATTAAAACTG -35 1 
CUAAUCUAAA GUUAUUAC UU UUCGAUCCUU GUUUUUUUUA ACCAGAUGAA snR5 
-35 0 GATTAGATTT CAATAATGAA AAGCTAGGAA CAAAAAAAAT TGGTCTACTT -30 1 
GGUCGGUAAA CGCGAAAUAU AUCUGUAUAC CUCCGCACUA CAGAAUUCGU snR5 
- 300 CCAGCCATTT GCGCTTTATA TAGACATATG GAGGCGTGAT GTCTTAAGCA -251 
ACCCAUUAGG CCUUCUAGUC AAAUAACUUA CUA' 5 snR5 
- 250 TGGGTAATCC GGAAGATCAG TTTATTGAAT GATGGTTTTC TTATCCTAAG -20 1 
- 200 GATCCTGCAA ATGAAGTAAG TTCAAAGAAT TGAAATGAAA TCGCCTTTTA -1 51 
-150 TACCCTCGCC GCACCAAGGA GCGCGCTGTA AAAT1'TTI'CG CTTTATCTCT - 101 
-100 TAGGGCTCCT ACTGTCGGTA GAGAAAAGTT GAGTATATIT AAAGCATGAG - 51 
-50 GTAACTTTTC TGCCCATTTT TACTTCTATT TCATTTGAAT TCAGAAAAGT - 1 
+1 GAAGCAAAAT TACACCATGA GTTCCTATTA ACGTCAGCCT CTTTTGTACT +50 
s n R31 GAAGCAAAAU UACACCAUGA GUUCCUAUUA ACGUCAGCCU CUUUUGUACU 
+51 CATAATGTGG CTTCGGATGT TTGATGGGCG TTGCTTCAGT GCGTACGGCT +100 
s n R3 1 CAUAAUGUGG CUUCGGAUGU UUGAUGGGCG UUGCUUCAGU GCGUACGGCU 
+101 CATGGTAGAT TAATTATTAG AAAGIITGTAT CTCCAGCTGT TGATATTIIGA +15 0 
s n R3 1 ChUGGUAGAU UAAUUAUUAG AAAGAUGUAU CUCCAGCUGU UGIIUAUUAGA 
+151 GGGGCAAGCC TTTCTCTTTC ACCTCGCCTT TTTAAACACC TGATACAGTT +200 
s o R31 GGGGGAAGCC UUUCUCUUUC ACCUCGCCUU UUUAAACACC UGAUACAGUU 
+201 GGTCATGATT CGTTCTACAT TTTAATTTCT TTATGTAACC ACGTTGTATA +250 
soR3 1 GGUCAUGAUU CGUUCUACAU UUUAAoH 
+251 TTTTCAATCT GGAAAGTAAC CTAAAAGAGT AAAAACTGTT TATTAAAAAA +300 
+3 01 AATGTTATTC AAAATTTATA CATAGTACAC GTACAGCTGC CTGAAGAAAG +350 
+351 CATGAGCGAA TGACTTATGC TTCGTCGTCT TCGTCTTCAC TTTCCAAAGC +400 
+4 01 AGCAAATGCG TTGAAA +4 16 
Figure 2. Sequence of the SNR5-SNR31 region. The sequence of SNR31 is shown, 
starting at + I . The inferred RNA sequence of snR31 (225 nt. ) is shown below 
the DNA sequence. The 5' flanking sequence is shown to -600. This region 
includes the SNR5 locus (5) ; the sequence of snRS is shown (in the 3 ' -5' 
orientation) above the DNA sequence (-217 is the 5' end, and -422 is the 3' 
end of snRS). Regions homologous to the box B and box C sequences previously 
described in other snoRNAs, are shown in bold in the snR31 sequence (box B 
is the more 5'). A line above nuc1eotides -148 to -155 denotes a potential TATA 
box region for SNR5 on the opposite strand. A potential TATA box region for 
SNR31 ( from -67 to -57) is underlined. 
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(Figure 1). This region was sequenced on both strands (Figure 
2) . The DNA sequence of this region has been submitted to the 
EMBL database under accession number X72299. Primer 
extension from within the presumed coding region gave a unique 
stop 217 bp from the 5' end of snR5 (Figure 2) . RNase protection 
using a riboprobe transcribed from the subcloned EcoR! - XmnI 
fragment (see Figure 1) confirmed that this is the correct 5' end 
of snR31. The 3 ' end was identified by RNase protection using 
a riboprobe transcribed from the subcloned XmnI - PvuII 
fragment (see Figure 1). This gave a single protected fragment. 
The size of the RNA predicted from the sequence, 225 nt., is 
in good agreement with the size predicted from the gel mobility 
of snR31. During the course of this work we learned that the 
SNR31 gene had been independently cloned by Balakin,A.G., 
Schneider,G.S., Corbett,M.S., Ni,J. and Fournier,M.J. 
(manuscript submitted for publication). 
To investigate whether snR31 is localized in the nucleolus, 
subnuclear fractionation was performed (Figure 3A). snR31 is 
retained in purified nuclei (Figure 3A, lane 2) as are the snoRNAs 
U3 and snR1O, and the snRNA U5. Comparison with a sample 
of whole cell RNA (Figure 3A, lane 1), shows that snR31 is 
recovered in the nuclear fraction with similar efficiency to that 
of the other snoRNAs. Extraction of nuclei with 2 % Triton-Xl14 
efficiently releases nucleoplasmic components (9 , 26). Nucleolar 
components, including snoRNAs, are retained, but can be 
released by extraction with a mixture of the ionic detergents 
sodium cholate and sodium deoxycholate (9, 23) . Triton 
extraction efficiently releases U5 (Figure 3A, lane 3) but U3, 
snR10 and snR31 are largely retained, and are released only by 
extraction with cholate/deoxycholate (Figure 3A, lane 4). 
Association of snR31 with nucleolar proteins was assessed by 
immunoprecipitation. Anti-NOPl antibodies precipitate all known 
yeast snoRNAs (9), and precipitate snR31 with an efficiency 
similar to that of snRI0 (Figure 3B, lane 5 and Figure 3C, lane 
3). Anti-GARl antibodies precipitate snR30 and snR1O, but only 
weakly precipitate U3 and U14 (10). snR31 is precipitated by 
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two different anti-GARl sera with an efficiency similar to that 
of snR30 or snR10 (Figure 3B, lanes 3 and 4). The nucleoplasmic 
snRNA U6 is not detectably precipitated by anti~NOPl or anti-G-
ARl antibodies. 
Immunoprecipitation was also used to determine whether snR31 
has the 5' tri-methyl guanosine (TMG) cap structure, which is 
present on all other yeast snoRNAs characterized to date except 
U14 and snRl90. Monoclonal antibodies against TMG 
immunoprecipitate snR31 with an efficiency similar to that of 
snR10 (Figure 3C, lane 2), which was shown by 2-dimensional 
thin layer chromatography to be quantitatively capped with TMG 
(27), or U3 (data not shown). 
To analyze its function, the SNR31 gene was deleted by a gene 
replacement technique (see Materials and Methods), in which 
the 5' 159nt. of the SNR31 coding region was replaced by the 
selective marker URA3. One copy of the SNR31 gene was initially 
replaced in a diploid strain. On sporulation, both the snr31::URA3 
and SNR31 haploid progeny could be recovered, showing that 
snR31 is not required for spore germination or cell growth. The 
SNR31 gene was disrupted in a haploid strain, allowing the direct 
comparison of otherwise isogenic snr31::URA3 and SNR31 
strains. The absence of snR31 from the snr31 ::URA3 strain was 
shown by Northern hybridization (Figure 4). The steady-state 
levels of other snoRNAs tested (snR1O, U3 and U14) were not 
altered by the absence of snR31 (Figure 4). Haploid snr31::URA3 
strains have a growth rate indistinguishable from that of isogenic 
SNR31 strains at a range of growth temperatures from 15° to 
37°C, on minimal and complex media and in the presence of 
elevated salt concentrations (data not shown). 
RNA was extracted from two independent snR31 ::URA3 strains 
and the isogenic SNR31 strain. To determine whether deletion 
of SNR31 has any effect on the processing ofpre-rRNA, Northern 
analyses were performed using probes specific for the transcribed 
pre-rRNA spacers (Figure 5). The only consistent difference is 
that the snr31::URA3 strain accumulates an elevated level of the 
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Figure 3. snR31 is a small nucleolar RNA. A. Sub-nuclear fractionation . Lane I , Total RNA. Lane 2, RNA recovered in the total nuclear fraction. Lane 3, RNA 
released by extraction with Triton X-114. Lane 4, RNA released by extraction with sodium cholate plus sodium deoxycholate. B. Immunoprecipitation with aGARI 
and aNOPI antibodies. Lane I, Total RNA from the lysate used for immunoprecipitation. Lane 2, RNA recovered following immunoprecipitation with non-immune 
rabbit serum. Lanes 3 -4, RNA recovered following immunoprecipitation with antibodies affinity purified against GARl from serum # 2 (lane 3), or from serum 
# 3 (lane 4). Lane 5, RNA recovered following immunoprecipitation with antibodies affinity purified against NOPl from serum ECl . RNA was recovered following 
immunoprecipitation, separated by PAGE, transferred to for Northern hybridization and hybridized with anti-sense riboprobes for the snoRNAs and snRNAs indicated. 
C. Immunoprecipitation with aTMG antibodies. Lane 1, Total RNA from lysate used for immunoprecipitation. Lane 2, RNA recovered following immunoprecipitation 
with monoclonal antibodies against tri-methyl guanosine. Lane 3, RNA recovered following immunoprecipitation with antibodies affinity purified against NOPl from 
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Figure 4. The snr31::URA3 mutation prevents synthesis of snR31. Lane 1, RNA 
extracted from an SNR31 strain. Lane 2, RNA extracted from an otherwise isogenic 
snr31::URA3 strain. Total RNA from each strain was separated by PAGE, 
transferred for Northern hybridization, and hybridized for the snoRNAs indicated. 








Figure 5. Processing of pre-rRNA in snr31::URA3 strains. Total RNA was 
extracted from an SNR31 strain (lanes 1 and 3) and an otherwise isogenic 
snr31::URA3 strain (lanes 2 and 4). The RNA was separated by electrophoresis 
on an agarose gel containing formaldehyde and transferred for Northern 
hybridization. Lanes I and 2 were hybridized with a probe specific for the 3' 
region of internal transcribed spacer I . Lanes 3 and 4 were hybridized with a 
probe specific for the 5' region of internal transcribed spacer 1. 
snr31 : : URA3 strains in five independent experiments. Phospho-
imager scanning of other Northern hybridizations shows that ratio 
of 35S pre-rRNA to its immediate product 32S pre-rRNA in the 
snr31::URA3 strains is 1.5 fold that of SNR31 strains (data not 
shown). This would be consistent with a mild reduction in the 
rate of processing of the 35S primary transcript of pre-rRNA. 
Other pre-rRNA species are not reproducibly altered by the 
absence of snR31. The absence of several other snoRNP 
components, the snoRNA U3, U14, snRlO and snR30 or the 
NOP1 , GARl and SOFl proteins (I , 2, 4, 10, 11,23,28), results 
in the accumulation of 35S, but in all of these cases this is 
associated with other alterations in the pathway of processing 
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leading to the synthesis of l8S rRNA. All of these mutations 
accumulate an aberrant 23S pre-rRNA species. Accumulation of 
23S is not seen in the snr31::URA3 strain; both of the probes 
shown in Figure 5 have the potential to hybridize to 23S pre-
rRNA, but no signal is detected by Northern hybridization. In 
addition, primer extension shows that the absence of any of the 
other above mentioned snoRNP components inhibits cleavage of 
the pre-rRNA at processing sites designated AI> which lies at 
the 5' end of the 18S rRNA coding region, and A2, which lies 
within internal transcribed spacer 1 (D.T., unpublished). In 
addition, genetic depletion of U3, SOFl or NOPl inhibits 
cleavage at site Aa, which lies within the 5' external transcribed 
spacer (I and D. T., unpublished). Primer extension analyses 
show that cleavage at none of these sites is altered by deletion 
of SNR31 (data not shown). 
The sequence of snR31 shows modest homology to that of 
another snoRNA, snRIO. Deletion of the SNR10 gene is not 
lethal, but results in an impairment ofpre-rRNA processing (4), 
suggesting the possibility that snRlO and snR31 might have 
redundant functions. To test this, snrlO- and snr31- strains 
were mated and sporulated, and the resulting tetrads were 
analyzed. The effects of deletion of SNRlO on pre-rRNA 
processing are greater than those of deletion of SNR31 and strains 
lacking both snRlO and snR3l were not detectably more impaired 
in growth or rRNA processing than sister strains lacking only 
snRlO (data not shown). This may indicate that snRlO is epistatic 
to snR31; the effects of disruption of SNRlO may mask the effects 
of disruption of SNR31, because it acts earlier in the processing 
pathway. 
DISCUSSION 
The sub-nuclear localization of snR31 and it's association with 
the nucleolar proteins NOPl and GARl clearly establish snR31 
as a novel snoRNA species. In higher eukaryotes, Ul4 and 
several other snoRNAs are excised from intronic sequences of 
larger transcripts (15-17, 29). In yeast, the genes encoding Ul4 
and snRl90 are very closely located (8) . These two species also 
differ from all other yeast snoRNAs in that they lack both 5' 
cap structures and obvious transcription signals. This suggests 
that yeast U14 and snR190 may also be excised from a larger 
transcript. In contrast, snR31 possesses as' cap structure, and 
a putative TATA element is located in the 5' flanking sequence 
of SNR31 (see Figure 2), making it likely that snR31 is directly 
transcribed by RNA polymerase IT. 
One of the most surprising results to emerge from the study 
of the yeast snoRNAs, is the number of non-essential species. 
Of 12 snoRNAs characterized, 8 (including snR31) have no 
detectable effects on cell growth when their genes are disrupted. 
These RNAs are presumably not without function, particularly 
as at least one of them, snR3, shows quite strong conservation 
between yeast and the very distantly related fIlarnentous fungus, 
Neurospora crassa (6). Moreover, recent reports indicate that 
comparably large numbers of snoRNAs are also present in higher 
eukaryotes. For two snoRNAs, U3 and U14, homologous RNAs 
have been identified from yeast and vertebrates; whether all 
snoRNAs will show a l: 1 correspondence between yeast and 
vertebrates is not yet clear. The results presented here show that 
snR3l, although not necessary for the maturation ofpre-rRNA, 
does appear to be required for optimum efficiency of the process. 
Several other yeast snoRNP components, the snoRNAs U3, U14, 
snRlO and snR30 and the snoRNP proteins NOPl, GARl and 
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SOFt , have been shown to be required for normal processing 
of the pre-rRNA (I, 2, 4, 10, ll, 23, 28). Genetic depletion 
of any of these components impairs the pathway leading to the 
synthesis of 18S rRNA, resulting in the absence of the normal 
processing intermediates, 32S, 27SA and 20S, and the appearance 
of an aberrant 23S pre-rRNA. In contrast, the absence of snR31 
results in the accumulation of the 35S primary transcript, 
consistent with a reduced rate of processing, but does not 
otherwise alter the processing pathway. 
By analogy to the roles of the nucleoplasmic snRNAs in mRNA 
splicing and processing, snoRNA mutants have been analyzed 
primarily for effects on pre-rRNA processing. It is, however , 
possible that they also play roles in other post-transcriptional steps 
in ribosome synthesis, such as modification of the pre-rRNA and 
ribosome assembly. Mutations in the nucleolar protein fibrillarin, 
which in yeast is encoded by the NOP 1 gene and is associated 
with all known snoRNAs, interfere with the modification of the 
pre-rRNA and ribosome assembly in addition to pre-rRNA 
processing (30) . This would be consistent with snoRNAs playing 
roles in all of these processes. The large number of snoRNAs 
present in both yeast and higher eukaryotes, would also be 
consistent with their having a range of functions . It is therefore 
possible that snR31 plays a role in some other aspect of ribosome 
synthesis, and that the observed, mild, processing defect is a 
secondary consequence of this impairment. 
ACKNOWLEDGEMENTS 
We would like to thank Hanna Lehtonen and Elizabeth Petfalski 
for technical assistance, John Morrissey for assistance with sub-
nuclear fractionation, Yves Henry and John Morrissey for critical 
comments on the manuscript, Reinhard Liihrmann for generously 
providing anti-TMG antibodies and, particularly, Elizabeth 
Schuster and Christine Guthrie for kindly giving us plasmid pES3 . 
REFERENCES 
I. Hughes,J .M.X. and Ares,MJr (1991) EMBO 1. 10,4231-4239. 
2. Li,H.V., Zagorski ,J . and Fournier,MJ. (1990) Mol. Cell. BioI. 10, 
1145-1152. 
3. Bally,M. , Hughes,J . and Cesareni,G. (1988) Nucleic Acids Res . 16, 
5291-5303 . 
4. Tollervey,D. (1987). EMBO 1. 6, 4169-4175. 
5. Parker,R., Simmons,T., Shuster,E.O., Siliciano,P.G. and Guthrie,c. (1988) 
Mol. Cell. BioI. 8, 3150-3159. 
6. Tollervey,D. , Wise,J.A. and Guthrie,C . (1983) Cell 35, 753-762. 
7. Thompson,J.R., Zagorski,J. , Woolford,J.L. and Foumier,MJ. (1988) Nucleic 
Acids Res. 16, 5587 - 5601. 
8. Zagorski,J., Tollervey,D. and Fournier,MJ . (1988) Mol. Cell. Bioi. 8, 
3282-3290. 
9. Schimmang,T. , Tollervey,D., Kern,H. , Frank,R. and Hurt,E.C . (1989) 
EMBO 1. 8, 4015-4024. 
10. Girard,J.P., Lehtonen,H., Caizergues-Ferrer,M., Amalric ,F., Tollervey,D. 
and Lapeyre,B. (1992) EMBO 1. 11, 673-682. 
11. Jansen,R., Tollervey,D. and Hurt,E.C. (1993) EMBO 1. 12, 2549-2558. 
12. Clarke,M.W., Yip,M.L.R. , Campbell,J. and Abelson,J. (1990) 1. Cell BioI. 
11, 1741-1751. 
13. Tyc,K. and Steitz,J.A. (1989) EMBO 1. 8, 3113-3119. 
14. Lui,J. and Maxwell,E.S. (1990) Nucleic Acids Res. 18, 6565-6571. 
15. Tycowski ,K.T., Shu,M.D. and Steitz,J.A. (1993) Genes Dev. 53 , 
1176-1190. 
16. Kiss,T. and Filipowicz,W. (1993) EMBO 1. 12,2913-2920. 
17. Fragapane,P., Prislei,S., Michienzi,A. Caffarelli,E. and Bozzoni,I. (1993) 
EMBO 1. 12, 2921-2928. 
18 . Ruff,E.A. , Rirnoldi,OJ., Raghu,B. and Eliceiri ,G.L. (1993) Proc. NaIl. 
Acad. Sci. USA 90, 635-638. 
19. Savino,R. and Gerbi,S.A. (1990) EMBO 1. 9, 2299-2308. 
20. Peculis,B.A. and Steitz,J.A. (1993). Cell 73, 1233 -1245 . 
21. Kass,S., Tyc,K., Steitz,J.A. and Sollner-Webb,B. (1990) Cell 60, 897-908. 
22 . Ito,H., Fukuda,Y., Murata,K. and Kimura,A. (1983). 1. Bacteriol. 153, 
163-168. 
23. Tollervey,D., Lehtonen,H., Carmo-Fonseca,M. and Hurt,E.C. (1991) EMBO 
1. 10, 573-583. 
24. Boorstein,W.R. and Craig,E.A. (1989) Methods Enzymol. 180, 347 - 369. 
25 . Melton,D .A. , Krieg,P.A., Rebagliati ,M.R., Maniatis,T., Zinn,K. and 
Green,M.R. (1984) Nucleic Acids Res. 12, 7035-7056. 
26. Hurt,E.C. , McDowall ,A. and Schirnrnang,T. (1988). Eur. 1. Cell. Bioi. 46, 
554-563. 
27. Wise,J.A., Tollervey,D. , Maloney ,D., Swerdlow,H., Dunn,E.J. and 
Guthrie,C. (1983) Cell 35, 743 -751. 
28 . Morrissey,J. and Tollervey,D. (1993) Mol. Cell. BioI. 13, 2469-2477. 
29. Leverette,R.D., Andrews,M.T. and Maxwell ,E.S. (1992) Cell 71 , 
1215-1221. 
30. Tollervey,D., Lehtonen,H., Jansen,R. , Kern,H. and Hurt,E.C .(1993). Cell 
72, 443 - 457. 
